, Volume 9, Issue 6, pp 435–442 | Cite as

Recent Advances in Therapy of Sepsis

Focus on Recombinant Bactericidal/Permeability-Increasing Protein (BPI)
  • Peter Elsbach
Leading Article


The inability to reduce the high mortality due to overwhelming bacterial infection and sepsis has prompted a search for new therapeutic agents. Among these may be a wide range of endogenous antibiotic polypeptides that are prominent components of effective antimicrobial host defences. One of these polypeptide antibiotics is the bactericidal/permeability-increasing protein (BPI), a protein of approximately 55kD which is present in human and other mammalian neutrophils. BPI is toxic for Gram-negative bacteria and binds to endotoxin, resulting in its clearance and neutralisation. Arecombinant 21kD N-terminal BPI fragment is at least as active as holo-BPI and protects both animals and humans against the effects of Gram-negative infections and their complications. Phase II/III clinical trials in fulminant paediatric meningococcaemia, haemorrhagic trauma, hepatectomy and severe peritoneal infections are in progress.


Adis International Limited Lipopolysaccharide Binding Protein Curr Opin Immunol Amino Terminal Fragment Antimicrobial Polypeptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Broekaert WF, Terras FR, Cammue BP, et al. Plant defensins: novel antimicrobial peptides as components of the host defense system. Plant Physiol 1995; 108(4): 1353–8PubMedCrossRefGoogle Scholar
  2. 2.
    Hoffmann JA. Innate immunity of insects. Curr Opin Immunol 1995; 7(1): 4–10PubMedCrossRefGoogle Scholar
  3. 3.
    Rietschel ET, Brade H, Holst O, et al. Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Curr Top Microbiol Immunol 1996; 216: 39-81Google Scholar
  4. 4.
    Neumann D, Glauser MR Pathogenesis of sepsis. Sci Am 1994 (Nov/Dec): 28–37Google Scholar
  5. 5.
    Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 326: 1153–7PubMedCrossRefGoogle Scholar
  6. 6.
    Warren HS. Strategies for the treatment of sepsis. N Engl J Med 1997; 336(13): 952–3PubMedCrossRefGoogle Scholar
  7. 7.
    Vadas P, Browning J, Edelson J, et al. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat 1993; 8(1): 1–30PubMedGoogle Scholar
  8. 8.
    Vadas P, Pruzanski W. Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock 1993; 39(2): 160–7PubMedGoogle Scholar
  9. 9.
    Elsbach P, Weiss J. Oxygen-independent antimicrobial systems of phagocytes. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: basic principles and clinical correlates. 2nd ed. New York: Raven Press, 1992: 603–36Google Scholar
  10. 10.
    Levy O. Antibiotic proteins of polymorphonuclear leukocytes. Eur J Haematol 1996; 56: 263–77PubMedCrossRefGoogle Scholar
  11. 11.
    Ganz T, Lehrer RI. Antimicrobial peptides of leukocytes. Curr Opin Hematol 1997; 4(1): 53–8PubMedCrossRefGoogle Scholar
  12. 12.
    Ouellette AJ, Selsted ME. Paneth cell defensins: endogenous peptide components of intestinal host defense. FASEB J 1996; 10(11): 1280–9PubMedGoogle Scholar
  13. 13.
    Diamond G, Russell JP, Bevins CL. Inducible expression of an antibiotic peptide gene in lipopolysaccharide-challenged tracheal epithelial cells. Proc Natl Acad Sci USA 1996; 93(10): 5156–60PubMedCrossRefGoogle Scholar
  14. 14.
    Weiss J. Leukocyte-derived antimicrobial proteins. Curr Opin Hematol 1994; 1: 78–84PubMedGoogle Scholar
  15. 15.
    Ganz T, Lehrer RI. Defensins. Curr Opin Immunol 1994; 6(4): 584–9PubMedCrossRefGoogle Scholar
  16. 16.
    Zanetti M, Gennaro R, Romeo D. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374(1): 1–5PubMedCrossRefGoogle Scholar
  17. 17.
    Ooi CE, Weiss J, Levy O, et al. Isolation of two isoforms of a novel 15-kDa protein from rabbit polymorphonuclear leukocytes that modulate the antibacterial actions of other leukocyte proteins. J Biol Chem 1990; 265(26): 15956–62PubMedGoogle Scholar
  18. 18.
    Levy O, Weiss J, Zarember K, et al. Antibacterial 15-kDa protein isoforms (p15s) are members of a novel family of leukocyte proteins. J Biol Chem 1993; 268(8): 6058–63PubMedGoogle Scholar
  19. 19.
    Levy O, Ooi CE, Weiss J, et al. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J Clin Invest 1994; 94(2): 672–82PubMedCrossRefGoogle Scholar
  20. 20.
    Zarember K, Elsbach P, Shin-Kim K, et al. p15s (15-kD antimicrobial proteins) are stored in the secondary granules of rabbit granulocytes: implications for antibacterial synergy with the bactericidal/permeability-increasing protein in inflammatory fluids. Blood 1997; 89: 672–9PubMedGoogle Scholar
  21. 21.
    Weiss J, Inada M, Elsbach P, et al. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes. J Biol Chem 1994; 269(42): 26331–7PubMedGoogle Scholar
  22. 22.
    Wright GC, Weiss J, Kim KS, et al. Bacterial phospholipid hydrolysis enhances the destruction of Escherichia coli ingested by rabbit neutrophils. Role of cellular and extracellular phospholipases. J Clin Invest 1990; 85(6): 1925–35PubMedCrossRefGoogle Scholar
  23. 23.
    Wright GW, Ooi CE, Weiss J, et al. Purification of a cellular (granulocyte) and an extracellular (serum) phospholipase A2 that participate in the destruction of Escherichia coli in a rabbit inflammatory exudate. J Biol Chem 1990; 265(12): 6675–81PubMedGoogle Scholar
  24. 24.
    Elsbach P, Weiss J. The bactericidal/permeability-increasing protein (BPI), a potent element in host-defense against gramnegative bacteria and lipopolysaccharide. Immunobiology 1993; 187(3–5): 417–29PubMedCrossRefGoogle Scholar
  25. 25.
    Elsbach P, Weiss J. Prospects for the use of recombinant BPI in the treatment of Gram-negative bacterial infections. Infect Agents Dis 1995; 4: 102–9PubMedGoogle Scholar
  26. 26.
    Larrick JW, Hirata M, Balint RF, et al. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995; 63(4): 1291–7PubMedGoogle Scholar
  27. 27.
    Lehrer RI, Ganz T. Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine-rich antimicrobial peptides. Ann NY Acad Sci 1996; 797: 228–39PubMedCrossRefGoogle Scholar
  28. 28.
    Weiss J, Elsbach P, Olsson I, et al. Purification and characterization of a potent bactericidal and membrane active protein from the granules of human polymorphonuclear leukocytes. J Biol Chem 1978; 253(8): 2664–72PubMedGoogle Scholar
  29. 29.
    Elsbach P, Weiss J, Franson RC, et al. Separation and purification of a potent bactericidal/permeability-increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes. Observations on their relationship. J Biol Chem 1979; 254(21): 11000–9PubMedGoogle Scholar
  30. 30.
    de Winter RJ, von der Mohlen MA, van Lieshout H, et al. Recombinant endotoxin-binding protein (rBPI23) attenuates endotoxin-induced circulatory changes in humans. J Inflamm 1995; 45(3): 193–206PubMedGoogle Scholar
  31. 31.
    von der Mohlen MA, Kimmings AN, Wedel NI, et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis 1995; 172(1): 144–51PubMedCrossRefGoogle Scholar
  32. 32.
    von der Mohlen MA, van Deventer SJ, Levi M, et al. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood 1995; 85(12): 3437–43PubMedGoogle Scholar
  33. 33.
    Gray PW, Flaggs G, Leong SR, et al. Cloning of the cDNA of a human neutrophil bactericidal protein. Structural and functional correlations. J Biol Chem 1989; 264(16): 9505–9PubMedGoogle Scholar
  34. 34.
    Gray PW, Corcorran AE, Eddy RL, et al. The genes for the lipopolysaccharide binding protein (LBP) and the bactericidal/permeability-increasing protein (BPI) are encoded in the same region of chromosome 20. Genomics 1993; 15: 188–90PubMedCrossRefGoogle Scholar
  35. 35.
    Leong SR, Camerata T. Nucleotide sequence of the bovine bactericidal permeability increasing protein (BPI). Nucleic Acids Res 1990; 18: 3052PubMedCrossRefGoogle Scholar
  36. 36.
    Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 Angstrom resolution. Science 1997; 276: 1881–4CrossRefGoogle Scholar
  37. 37.
    Ooi CE, Weiss J, Elsbach P, et al. A 25-kDa NH2 -terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability-increasing protein. J Biol Chem 1987; 262(31): 14891–4PubMedGoogle Scholar
  38. 38.
    Ooi CE, Weiss J, Doerfler ME, et al. Endotoxin-neutralizing properties of the 25 kD N-terminal fragment and a newly isolated 30 kD C-terminal fragment of the 55–60 kD bactericidal/permeability-increasing protein of human neutrophils. J Exp Med 1991; 174(3): 649–55PubMedCrossRefGoogle Scholar
  39. 39.
    Weiss J, Elsbach P, Shu C, et al. Human bactericidal/permeability-increasing protein and a recombinant NH2 -terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 1992; 90(3): 1122–30PubMedCrossRefGoogle Scholar
  40. 40.
    Weiss J, Olsson I. Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. Blood 1987; 69(2): 652–9PubMedGoogle Scholar
  41. 41.
    Weersink AJ, van Kessel KP, van den Tol ME, et al. Human granulocytes express a 55-kDa lipopolysaccharide-binding protein on the cell surface that is identical to the bactericidal/permeability-increasing protein. J Immunol 1993; 150(1): 253–63PubMedGoogle Scholar
  42. 42.
    Dentener MA, Francot GJ, Buurman WA. Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. J Infect Dis 1996; 173(1): 252–5PubMedCrossRefGoogle Scholar
  43. 43.
    Gazzano-Santoro H, Parent JB, Grinna L, et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun 1992; 60(11): 4754–61PubMedGoogle Scholar
  44. 44.
    Mannion BA, Weiss J, Elsbach P. Separation of sublethal and lethal effects of polymorphonuclear leukocytes on Escherichia coli. J Clin Invest 1990; 86(2): 631–41PubMedCrossRefGoogle Scholar
  45. 45.
    Mannion BA, Weiss J, Elsbach P. Separation of sublethal and lethal effects of the bactericidal/permeability increasing protein on Escherichia coli. J Clin Invest 1990; 85(3): 853–60PubMedCrossRefGoogle Scholar
  46. 46.
    Marra MN, Wilde CG, Griffith JE, et al. Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 1990; 144(2): 662–6PubMedGoogle Scholar
  47. 47.
    Marra MN, Wilde CG, Collins MS, et al. The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992; 148(2): 532–7PubMedGoogle Scholar
  48. 48.
    Weinrauch Y, Foreman A, Shu C, et al. Extracellular Accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate. J Clin Invest 1995; 95: 1916–24PubMedCrossRefGoogle Scholar
  49. 49.
    Iovine N, Elsbach P, Weiss J. An opsonic function of the neutrophil bactericidal/permeability-increasing protein depends on both its N- and C-terminal domains. Proc Natl Acad Sci USA 1997; 94: 10973–8PubMedCrossRefGoogle Scholar
  50. 50.
    Schumann RR, Leong SR, Flaggs GW, et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249(4975): 1429–31PubMedCrossRefGoogle Scholar
  51. 51.
    Ulevitch RJ, Dunn DL, Fink MP, et al. Endotoxin-related intra-cellular pathways: implications for therapeutic intervention. Shock 1996; 6(1): 1–2PubMedCrossRefGoogle Scholar
  52. 52.
    Gazzano-Santoro H, Meszaros K, Birr C, et al. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and Gram-negative bacteria. Infect Immun 1994; 62: 1185–91PubMedGoogle Scholar
  53. 53.
    Gazzano-Santoro H, Parent JB, Conlon PJ, et al. Characterization of the structural elements in lipid A required for binding of a recombinant fragment of bactericidal/permeability-increasing protein rBPI23. Infect Immun 1995; 63: 2201–5PubMedGoogle Scholar
  54. 54.
    Ulevitch RJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol 1994; 6(1): 125–30PubMedCrossRefGoogle Scholar
  55. 55.
    Dentener MA, Von Asmuth E, Francot GJ, et al. Antagonistic effects of lipopolysaccharide binding protein and bactericidal/permeability-increasing protein on lipopolysaccharide-induced cytokine release by mononuclear phagocytes. Competition for binding to lipopolysaccharide. J Immunol 1993; 151(8): 4258–65PubMedGoogle Scholar
  56. 56.
    Tobias PS, Soldau K, Iovine N, et al. Lipopolysaccharide (LPS) binding proteins BPI and LBP form different complexes with LPS. J Biol Chem 1997; 272(30): 18682–5PubMedCrossRefGoogle Scholar
  57. 57.
    Katz SS, Chen K, Chen S, et al. Potent CD14-mediated signalling of human leukocytes by Escherichia coli can be mediated by interaction of whole bacteria and host cells without extensive prior release of endotoxin. Infect Immun 1996; 64: 3592–600PubMedGoogle Scholar
  58. 58.
    Tobias PS, Soldau K, Gegner JA, et al. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem 1995; 270(18): 10482–8PubMedCrossRefGoogle Scholar
  59. 59.
    Ammons WS, Kohn FR, Kung AHC. Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of Gram-negative sepsis: role of bactericidal properties. J Infect Dis 1994; 170: 1473–82PubMedCrossRefGoogle Scholar
  60. 60.
    Kung AH, Ammons WS, Lin Y, et al. Efficacy of a recombinant amino terminal fragment of bactericidal/permeability increasing protein in rodents challenged with LPS or E. coli bacteria. Prog Clin Biol Res 1994; 388: 255–63PubMedGoogle Scholar
  61. 61.
    Lin Y, Kohn FR, Kung AH, et al. Protective effect of a recombinant fragment of bactericidal/permeability increasing protein against carbohydrate dyshomeostasis and tumor necrosis factor-alpha elevation in rat endotoxemia. Biochem Pharmacol 1994; 47(9): 1553–9PubMedCrossRefGoogle Scholar
  62. 62.
    Lin Y, Ammons WS, Leach WJ, et al. Protective effects of a recombinant N-terminal fragment of bactericidal/permeability increasing protein on endotoxic shock in conscious rabbits. Shock 1994; 2(5): 324–31PubMedCrossRefGoogle Scholar
  63. 63.
    Lin Y, Leach WJ, Ammons WS. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability-increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrob Agents Chemother 1996; 40(1): 65–9PubMedGoogle Scholar
  64. 64.
    Giroir BP, Quint PA, Barton P, et al. Evaluation of rBPI21 (recombinant amino terminal fragment of human bactericidal/permeability-increasing protein) in children with severe meningococcal disease. Lancet 1997; 350: 1439–43PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Departments of Medicine and MicrobiologyNew York University School of MedicineNew YorkUSA

Personalised recommendations